Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

88 results about "Concentration dependent" patented technology

Concentration dependent (time independent) means that the rate and extent of microorganism killing are a function of the antimicrobial concentration (increase as the concentration increases).

Methods and kits for assays of rapid screening of diabetes

The invention provides an in vivo screening assay and an in vitro screening assay for rapid screening of diabetes. A method of the invention includes determining a first glucose concentration in an ocular fluid of a patient; administering orally a load of carbohydrate to the patient; determining a second glucose concentration in an ocular fluid of the patient at a period of time of less than 50 minutes after orally administering of the load of carbohydrate; comparing the second glucose concentration with the first glucose concentration to determine if the patient is likely to be a diabetic. The method of the invention is performed by using a kit of the invention. The kit comprises: (1) a glucose-sensing ophthalmic device and instructions for using the glucose-sensing ophthalmic device to screen for diabetes; or (2) two or more tear-collecting devices, and a testing agent composition which specifically reacts with glucose to form a detectable signal. The glucose-sensing ophthalmic device comprises a testing agent composition which specifically and reversibly interacts with glucose to form a detectable optical signal which changes in a concentration-dependent manner.
Owner:MORRIS CAROL ANN +2

Proteins, Sensors, and Methods of Characterizing Analytes Using the Same

A protein sensing molecule is capable of binding an analyte in a sample. The protein sensing molecule includes a first detectable quality that changes in a concentration dependent manner when the protein sensing molecule is bound to the analyte. The protein sensing molecule also includes a second detectable quality that does not undergo substantial change when the protein sensing molecule is bound to the analyte. The protein sensing molecule may be used in methods for characterizing samples and may also be used in sensors.
Owner:UNIV OF MARYLAND BALTIMORE COUNTY

Mosfet having a high stress in the channel region

Source and drain extension regions are selectively removed by a dopant concentration dependent etch or a doping type dependent etch, and an embedded stress-generating material such as SiGe alloy or a Si:C alloy in the source and drain extension regions is grown on a semiconductor substrate. The embedded stress-generating material may be grown only in the source and drain extension regions, or in the source and drain extension regions and in deep source and drain regions. In one embodiment, an etch process that removes doped semiconductor regions of one conductivity type selective to doped semiconductor regions of another conductivity type may be employed. In another embodiment, a dopant concentration dependent etch process that removes doped semiconductor regions irrespective of the conductivity type selective to undoped semiconductor regions may be employed.
Owner:GLOBALFOUNDRIES INC

Reagentless and reusable biosensors with tunable differential binding affinities and methods of making

The biosensor comprises a modular biorecognition element and a modular flexible arm element. The biorecognition element and the flexible arm element are each labeled with a signaling element. The flexible arm contains an analog of an analyte of interest that binds with the biorecognition element, bringing the two signaling elements in close proximity, which establishes a baseline fluorescence resonance energy transfer (FRET). When an analyte of interest is provided to the biosensor, the analyte will displace the analyte analog, and with it, the signaling module of the modular flexible arm, causing a measurable change in the FRET signal in a analyte concentration dependent manner. The modularity of different portions of the biosensor allows functional flexibility. The biosensor-operates without additional development reagents, requiring only the presence of analyte or target for function.
Owner:USA AS REPRESENTED BY THE SEC OF THE NAVY THE

Headspace instrument

A headspace instrument (10, 70) operates to equilibrate a vapor phase of a headspace sample in a sample loop (40, 74). The sample is equilibrated by flow through the headspace between variable volume chambers (28, 50, 86, 90). The volume of the variable volume chambers are changed in coordinated relation so that a constant total volume is always maintained. An aliquot of the equilibrated sample in the sample loop is delivered to an analytical instrument. The headspace instrument enables delivering a vapor sample from a headspace under conditions which do not disturb the thermodynamic equilibrium between the vapor phase and the non-vapor phase of the sample and avoids having the sampling process impact the results of the analysis. Alternative forms of the headspace instrument enable the conduct of concentration dependent processes and absorption and desorption experiments.
Owner:MARKELOV MICHAEL +1

Plastic surfaces and apparatuses for reduced adsorption of solutes and methods of preparing the same

A method of treating a plastic surface with fluorine gas to decrease adsorption of hydrophobic solute molecules to the surface is provided. The method can include treating a surface with a first gas comprising fluorine gas and a second gas comprising oxygen gas, water vapor, or both oxygen gas and water vapor. Plastics treated using the method provide useful drug discovery and biochemical tools for the testing, handling, and storage of solutions containing low concentrations of hydrophobic solutes. Microfluidic devices containing treated plastic interior surfaces and methods of using such devices to make concentration-dependent measurements are also described.
Owner:SCIEX

Ion concentration-dependent binding molecule library

Disclosed is a library consisting essentially of a plurality of antigen-binding molecules differing in sequence from each other, wherein an antigen-binding domain in each of the antigen-binding molecules comprises at least one amino acid residue that changes the antigen-binding activity of the antigen-binding molecule depending on ion concentration conditions. Also disclosed are a composition comprising a plurality of polynucleotide molecules each encoding the antigen-binding molecules, a composition comprising a plurality of vectors each comprising the polynucleotide molecules, a method for selecting the antigen-binding molecules, a method for isolating the polynucleotide molecules, a method for producing the antigen-binding molecules, and a pharmaceutical composition comprising any of the antigen-binding molecules.
Owner:CHUGAI PHARMA CO LTD

Compositions and methods for modulation of vascular structure and/or function

InactiveUS20020019367A1Minimizing blood lossCessationBiocideSolution deliveryArteriolar VasoconstrictionVascular structure
The present invention relates to compositions comprising semi-crystalline beta-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and / or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and / or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a beta-1-4 conformation.
Owner:MARINE POLYMER TECH

Protective agent for retinal neuronal cell containing prostaglandin f2alpha derivative as active ingredient

InactiveUS20090234005A1Prevention or treatment of an eye diseaseReduce usageBiocideSenses disorderCell damageProstaglandin F2alpha
An object of the present invention is to find a new pharmaceutical application of a prostaglandin F2α derivative. It was found that the prostaglandin F2α derivative inhibits glutamate-induced retinal neuronal cell death in a concentration-dependent manner in rat fetal retinal neuronal cells, in other words, the prostaglandin F2α derivative acts directly on the retinal neuronal cells and exhibits a protective effect. Accordingly, the prostaglandin F2α derivative is useful for the prevention or treatment of an eye disease associated with retinal neuronal cell damage.
Owner:ASAHI GLASS CO LTD +1

Mammalian dihydroouabain-like factor and therapeutic compositions

A novel mammalian dihydroouabain-like factor is disclosed which substantially fails to cross-react with mammalian ouabain-like factor (OLF) for binding to anti-OLF antibody, but cross-reacts with plant-related dihydroouabain (dho) for binding to anti-dho antibody, has maximal u.v. absorbance at 196 nm, has a non-peptidic, non-lipidic chemical structure and a fully hydrogenated lactone ring, has a concentration-dependent Na<+>,K<+>-ATPase (sodium pump) catalytic inhibitory activity which is 10-fold lower than OLF and 3-fold higher than plant-related dihydroouabain, and a high pressure liquid chromatography elution time about the same as dho. This factor is useful for therapy for congestive heart failure. An antibody and antibody fragments having affinity for mammalian Dh-OLF but not for OLF, and diagnostic and therapeutic methods comprise the antibody and means for quantifying the antibody and are useful for treating a condition caused by high level of OLF or Dh-OLF. Two isomers of plant-related dihydroouabain have been isolated. These compositions and methods are suitable for characterizing a variety of diseases and conditions associated with reduced sodium pump activity.
Owner:UNIV OF LOUISVILLE RES FOUND INC

Pharmaceutical composition comprising hydroxylated nebivolol

Hydroxylated nebivolol metabolites increase NO release in human endothelial cell preparations in a concentration-dependent manner after acute administration. In addition, hydroxylated nebivolol metabolites (including but not limited to 4-hydroxy-6,6'difluoro) have the ability to increase NO release in human endothelial cells after chronic administration. The present invention provides hydroxylated nebivolol metabolites for use in the treatment of cardiovascular diseases. Furthermore, the present invention provides methods of treating and / or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol capable of releasing a therapeutically effective amount of nebivolol to targets affected by vascular diseases. Nitric oxide.
Owner:MYLAN LAB INC (US)

Bioactive fraction from zingier officinale and a process for the preparation thereof

Ulcer is a serious oxidative stress induced disease with complex pathologic events including upregulation of H+K+ ATPase of parietal cell (PC) membrane, damage of mucin layer around PC, PC-DNA damage etc. The polysaccharide (GRPP) fraction and antioxidant extract (GRAOX) of ginger was examined for their ability to inhibit H+ K+ ATPase. Results indicated that the inhibition of H+ K+ ATPase activity which causes acidity in the lumen of the stomach, also exhibited better H+K+ ATPase inhibition (PPI) at the IC50 of 27.2 μg (GRPP) and 16.5 μg GAE (AOX) respectively than the known antiulcer proton pump blocker Lansoprazole (19.3 μg). Further the antioxidant activity in antioxidant extract (GRAOX) by various assay systems was examined such as Reducing power, Free radical scavenging (FRS), DNA and cytoprotection systems etc. GRAOX exhibited concentration dependent reducing power ability at 5-25 g equivalent of phenol. FRS activity with IC50 of 6.8 μg equivalent of phenol etc. At 0.3 μg level GRAOX offered >80% protection to DNA and against FeSO4-Asc'orbate induced oxidation. The major active phenolic components were identified as Gallic acid / Tannic acid (46%), and Cinnamic acid (51%).
Owner:COUNCIL OF SCI & IND RES

Methods and kits for assays of rapid screening of diabetes

The invention provides an in vivo screening assay and an in vitro screening assay for rapid screening of diabetes. A method of the invention includes determining a first glucose concentration in an ocular fluid of a patient; administering orally a load of carbohydrate to the patient; determining a second glucose concentration in an ocular fluid of the patient at a period of time of less than 50 minutes after orally administering of the load of carbohydrate; comparing the second glucose concentration with the first glucose concentration to determine if the patient is likely to be a diabetic. The method of the invention is performed by using a kit of the invention. The kit comprises: (1) a glucose-sensing ophthalmic device and instructions for using the glucose-sensing ophthalmic device to screen for diabetes; or (2) two or more tear-collecting devices, and a testing agent composition which specifically reacts with glucose to form a detectable signal. The glucose-sensing ophthalmic device comprises a testing agent composition which specifically and reversibly interacts with glucose to form a detectable optical signal which changes in a concentration-dependent manner.
Owner:NOVARTIS AG

Antibody capable of recognizing HLA class i

An objective of the present invention is to provide antibodies that recognize HLA class I and have significant cell death-inducing activity. To achieve the above objective, first, the present inventors immunized mice with soluble HLA-A to which a FLAG tag is attached. Four days after the final immunization, spleen cells from the mice were fused with mouse myeloma cells. Then, hybridoma screening was carried out using the cell aggregation-inducing activity and cell death-inducing activity as an index. Thus, the monoclonal antibody F17B1 that has strong cell death-inducing activity was selected. The sequences of the H chain and L chain variable regions of the mouse monoclonal antibody F17B1 were determined to humanize this antibody. Then, the humanized anti-HLA class I antibody H2-G1d_L1-k0 was assessed for cell death induction. The result showed that H2-G1d_L1-k0 suppressed the growth of the IM9 cell line in a concentration dependent manner.
Owner:CHUGAI PHARMA CO LTD

Anti-tumor application of tanshinone compound

The invention relates to an application of a tanshinone compound in preparing anti-tumor medicaments, and the prepared medicaments can resist tumors, such as brain tumors, lung cancer, liver caner, breast cancer, prostatic cancer, pancreatic cancer, cervical cancer, gastric cancer, esophagus cancer, and the like. Proved by experiments, the tanshinone compound is concentration-dependent to suppress the proliferation of tumor cells. The compound can obviously induce the expression of quinone reductase and obviously suppress the generation of tumor vessels, thus the compound can also be used for preparing cancer chemical prevention medicaments, anti-inflammatory medicaments and medicaments for suppressing the generation of the tumor vessels. Frequently used low-price reagents, such as alcohol, chloroform, methanol, silica gel, and the like, are used for separating tanshinone compound monomers from medicinal materials. The method is simple and reliable, has low cost and high efficiency, can be used for carrying out industrialized mass production and is beneficial to popularization and application. The tanshinone compound has a structural general formula disclosed in the specification.
Owner:ZHEJIANG UNIV

Reagentless and Reusable Biosensors with Tunable Differential Binding Affinities and Methods of Making

The biosensor comprises a modular biorecognition element and a modular flexible arm element. The biorecognition element and the flexible arm element are each labeled with a signaling element. The flexible arm contains an analog of an analyte of interest that binds with the biorecognition element, bringing the two signaling elements in close proximity, which establishes a baseline fluorescence resonance energy transfer (FRET). When an analyte of interest is provided to the biosensor, the analyte will displace the analyte analog, and with it, the signaling module of the modular flexible arm, causing a measurable change in the FRET signal in a analyte concentration dependent manner. The modularity of different portions of the biosensor allows functional flexibility. The biosensor operates without additional development reagents, requiring only the presence of analyte or target for function.
Owner:NAVY USA AS REPRESENTED BY THE SEC OF THE THE

Polyfunctional dispersants for controlling viscosity of phyllosilicates

InactiveUS7081483B2Impart corrosion inhibiting propertyImprove dispersabilityOther chemical processesMixing methodsHigh concentrationPolymer science
This invention provides phyllosilicates and polyfunctional dispersants which can be manipulated to selectively control the viscosity of phyllosilicate slurries. The polyfunctional dispersants used in the present invention, which include at least three functional groups, increase the dispersion and exfoliation of phyllosilicates in polymers and, when used in conjunction with phyllosilicate slurries, significantly reduce the viscosity of slurries having high concentrations of phyllosilicates. The functional groups of the polyfunctional dispersants are capable of associating with multivalent metal cations and low molecular weight organic polymers, which can be manipulated to substantially increase or decrease the viscosity of the slurry in a concentration dependent manner. The polyfunctional dispersants of the present invention can also impart desirable properties on the phyllosilicate dispersions including corrosion inhibition and enhanced exfoliation of the phyllosilicate platelets.
Owner:CHICAGO UNIV OF THE +1

Small peptide capable of resisting thrombosis and platelet aggregation

The invention discloses a small peptide capable of resisting thrombosis and platelet aggregation, and the sequence of the small peptide is X-Arg-Y-X-Lys, wherein X refers to nonpolar amino acid and the nonpolar amino acid includes alanine, valine, leucine, isoleucine, proline or phenylalanine; while Y refers to polar amino acid and the polar amino acid is glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid or glutamic acid. An in vitro platelet aggregation test and an in vivo thrombosis test show that the small peptide can restrain platelet aggregation in a concentration dependent way and simultaneously can remarkably restrain thrombosis of artery-vein bypass in bodies of rats. The small peptide and derivatives of the small peptide can be used for resisting platelet aggregation and thrombosis in treatment. The small peptide can be used for preparing medicaments resisting thrombosis and platelet aggregation.
Owner:SOUTHEAST UNIV

Luminescent carbon quantum dot and preparation method and application thereof

InactiveCN109810698AFluorescent light color adjustableRealize solid state light emissionSolid-state devicesSemiconductor/solid-state device manufacturingSolvothermal reactionLight-emitting diode
The invention provides a luminescent carbon quantum dot and a preparation method and application thereof, and belongs to the technical field of nano materials. The luminescent carbon quantum dot adopts small organic molecules as raw materials, the raw materials are cheap and easy to obtain, and the production cost can be effectively reduced; a solvothermal reaction is used for preparing the luminescent carbon quantum dot, the reaction raw materials do not need pretreatment, the preparation process is simple, the reaction conditions are easy to control, and the industrialized production is easyto realize; and the preparation method can prepare a liquid luminescent carbon quantum dot and a solid-state luminescent carbon quantum dot, wherein the liquid luminescent carbon quantum dot has concentration-dependent fluorescence emission characteristics and is adjustable in fluorescent color, and the solid-state carbon quantum dot can realize solid-state illumination of the carbon quantum dot.The luminescent carbon quantum dot can be used in the fields of fluorescence detection of heavy metal ions and organic small molecules, fluorescence imaging of non-therapeutic cells and light-emitting diodes.
Owner:NORTHEAST FORESTRY UNIVERSITY

Process for preparing antioxidative peptide and antifreeze peptide through enzymatic hydrolysis of salmon collagens

The invention discloses a process for simultaneously preparing an antioxidative peptide and an antifreeze peptide through enzymolysis of collagens. The method comprises the following steps: extractingcollagens by taking salmon skin as a raw material, hydrolyzing the collagens into a short peptide solution by utilizing crude enzymes of extracellaluar protease obtained by fermentation of Vibrio sp.SQS2-3, performing centrifugal ultrafiltration by a 3000 Da ultrafiltration tube 4500*g for 45 minutes so as to obtain the antifreeze peptide with effects of protecting myosin and relieving decreaseof Ca<2+>-ATPase activity in multigelation, performing Sephadex LH-20 gel filtration chromatography to separate lower ultrafiltration components so as to obtain the antioxidative peptide which has effects of scavenging DPPH free radicals and hydroxyl radicals and a certain ability of inhibiting DNA oxidative damage and shows concentration-dependent antioxidant activity in oxygen radical absorptioncapacity detection. The LC-MS technology shows that the antioxidant component contains 19 polypeptides.
Owner:CENT SOUTH UNIV

Measurement of oxygen

An oxygen number density or concentration sensor including a sampling luminescent oxygen probe located in a fluid environment, and a gas impermeable enclosure located in the fluid environment and a reference luminescent oxygen probe located within the gas impermeable enclosure, wherein the sampling and reference luminescent oxygen probes are formed by an ideal PSP. A predetermined fixed oxygen number density or concentration is provided within a medium contained in the gas impermeable enclosure. A detector receives signals corresponding to luminescent emissions of the sampling and reference probes. A processor determines a number density or concentration of oxygen in the fluid environment from a signal generated at the sampling probe with reference to an oxygen number density or concentration dependent signal generated at the reference probe.
Owner:INNOVATIVE SCI SOLUTIONS

Preparation method of transgenetic zebrafish used for detecting environment pollutants

A disclosed preparation method of transgenetic zebrafish used for detecting environment pollutants comprises: (1) cloning the promoter regulatory sequence of Mdr1 protein from zebrafish genome; (2) fusing the DNA fragment obtained by cloning into the upstream of GFP coding sequence for constructing an expression vector; (3) performing zebrafish embryo microinjection on the expression vector; (4) culturing the embryo subjected to injection to sexual maturity, and enabling cultured zebrafish and wide zebrafish to copulate and oviposit; and (5) screening positive F1 generation under a fluorescence microscope, and performing inbreeding to obtain F2 generation and further to obtain a transgenic line with stable inheritance. Because the expression level of fluorescin can be induced in a concentration dependent way by multiple environment pollutants such as heavy metals, polycyclic aromatic hydrocarbons and the like, the transgenic zebrafish prepared by employing the preparation method can be used to detecting the existence and the concentration of the above chemical pollutants in environment; and the preparation method has the advantages of being economic, rapid, convenient and accurate.
Owner:SUZHOU INST OF BIOMEDICAL ENG & TECH CHINESE ACADEMY OF SCI

Application of bavachalcone and analogues thereof

InactiveCN105982881ANervous disorderAntipyreticDiseaseCircadian clock gene
The invention discloses a use of psoralen chalcone and its analogues. The use refers to the use of psoralen chalcone or / and its analogues as active ingredients for the preparation of activating retinoic acid-related orphan nuclear receptors. Body-alpha composition. The research results of the present invention show that psoralen chalcone and its analogs can directly activate the activity of RORα in a dose-dependent manner, and activate the expression of RORα protein and RORα mRNA in a concentration-dependent manner, and can effectively regulate its downstream biological clock genes The expression of BMAL1 indicates that psoralen chalcone and its analogues are good positive activators of RORα, which can be used to prevent or treat related diseases mediated by RORα, and have broad application prospects.
Owner:SHANGHAI UNIV OF T C M

Compound separated and extracted from marine penicillium and application thereof

InactiveCN101811959AInhibition of quorum sensing is obviousPenicillium marine strains are easy to obtainAntibacterial agentsOrganic active ingredientsVirulent characteristicsWild type
The invention belongs to the technical field of preparing compounds, and relates to a compound separated and extracted from marine penicillium and application thereof. The compound is used for preventing and treating in-vitra and in-vivo pseudomonas aeruginosa infection of people or animals, and the chemical formula of the compound which is obtained by fermenting the marine penicillium and has the effect of inhibiting quorum sensing of pseudomonas aeruginosa is 4,6-dimethyl-7-[(1R,2E,4aS,7R,8R,8aR)-1,2.4a,5,6,7,8,8a-octahydro-7-hydroxyl-2-(3-hydroxyl-2-oxygen-propylene)-3,6,8-trimethyl-1-naphthyl]-,(2E,4E,6E)-heptantriene acid, and the molecular formula of the compound is C25H34O5; the compound does not inhibit the growth of the wild type pseudomonas aeruginosa; the quorum-sensing inhibition effect of the compound is concentration-dependent, and is gradually strengthened with the increase of the concentration; virulence factors controlled by the quorum sensing of the pseudomonas aeruginosa can be inhibited; and the compound also has the advantages of readily available raw materials, simple and easily controlled preparation process, obvious sensing inhibition effect and prominent social benefits.
Owner:OCEAN UNIV OF CHINA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products